Citi on Celldex Therapeutics (CLDX): 'Competitor CSU Data Unclear Under the Surface; Positive Readthrough for Celldex'
Tweet Send to a Friend
Citi analyst David Lebowitz reiterated a Buy rating and $70.00 price target on Celldex Therapeutics (NASDAQ: CLDX)The analyst comments "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
